Jonathan J Miner, MD, PhD

Rheumatology
Accepting new patients
Sees patients age 18 and up
Penn Rheumatology Perelman
Schedule onlineCall 215-662-4333
Headshot of Jonathan J Miner, MD, PhD
Penn Medicine Provider

About me

  • Associate Professor of Medicine (Rheumatology)
  • Associate Professor of Medicine in Microbiology

My education and training

  • Medical School: University of Oklahoma
  • Residency: Barnes-Jewish Hospital - Washington University, St. Louis
  • Fellowship: Barnes-Jewish Hospital - Washington University, St. Louis

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Miner is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Poddar S, Chauvin SD, Archer CH, Qian W, Castillo-Badillo J, Yin X, Disbennett WM, Miner A, Holley JA, Naismith T, Stinson WA, Wei X, Ning Y, Fu J, Ochoa TA, Surve N, Zaver S A, Wodzanowski KA, Balka KR, Venkatraman R, Liu C, Rome K, Bailis W, Shiba Y, Cherry S, Shin S, Semenkovich CF, De Nardo D, Yoh S, Roberson EDO, Chanda SK, Kast DJ, and Miner JJ. ArfGAP2 promotes STING proton channel activity, cytokine transit, and autoinflammation. , Cell: 2025

Chauvin SD, Holley JA, Poddar S, Miner CA, Kumble L, Fu J, Laue-Gizzi H, Hardy TA, Miner JJ. Prime editor gene therapy and TREX1 mosaicism in retinal vasculopathy with cerebral leukoencephalopathy. , J Clin Immunol, 41(1): 2024,54

Chauvin SD, Ando S, Holley JA, Sugie A, Zhao FR, Poddar S, Kato R, Miner CA, Nitta Y, Krishnamurthy SR, Saito R, Ning Y, Hatano Y, Kitahara S, Koide S, Stinson WA, Fu J, Surve N, Kumble L, Qian W, Polishchuk O, Andhey PS, Chiang C, Liu G, Colombeau L, Rodriguez R, Manel N, Kakita A, Artyomov MN, Schultz DC, Coates PT, Roberson EDO, Belkaid Y, Greenberg RA, Cherry S, Gack MU, Hardy T, Onodera O, Kato T, Miner JJ. Inherited C-terminal TREX1 variants disrupt homology-directed repair to cause senescence and DNA damage phenotypes in Drosophila, mice, and humans. , Nature Communications, 15(1): 2024,4696

Miner JJ, Fitzgerald KA. A path towards personalized medicine for autoinflammatory and related diseases , Nature Reviews Rheumatol, 19(3): 2023,182-189

Chauvin SD, Stinson WA, Platt DJ, Poddar S, Miner JJ. Regulation of cGAS and STING signaling during inflammation and infection , Journal of Biological Chemistry, 299(7): 2023,104866

Platt DJ, Lawrence D, Qian W, Rodger R, Schriefer L, Miner CA, Menos AM, Kennedy EA, Peterson ST, Stinson WA, Baldridge MT, Miner, JJ Transferrable protection by gut microbes against STING-associated lung disease , Cell Rep, 35(6): 2021,109133

Bennion BG, Croft CA, Ai TL, Qian W, Menos AM, Miner CA, Fremond ML, Doisne JM, Andhey PS, Platt DJ, Bando JK, Wang ER, Luksch H, Molina TJ, Robison EDO, Artyomov MN, Rosen-Wolff A, Colonna M, Rieux-Laucat F, Di Santo JP, Neven B, Miner JJ. STING gain-of-function disrupts lymph node organogenesis and innate lymphoid cell development in mice. , Cell Rep, 31(11): 2020,107771

Luksch H, Stinson WA, Platt DJ, Qian W, Kalugotla G, Miner CA, Bennion BG, Gerbaulet A, Rösen-Wolff A, Miner JJ. STING-associated lung disease in mice relies on T cells but not type I interferon , J Allergy Clin Immunol, 144(1): 2019,154-266

View all publications